Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer

NCT00558545 is registered in ClinicalTrials.gov with Aegera Therapeutics as lead sponsor.

NCT NCT00558545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00558545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer
Lead sponsor
Aegera Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2007
Completion date
May 31, 2009
Enrollment
61 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

human mammary carcinoma